Sepsis Diagnostics Market

The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is growing steadily, driven by the high incidence of sepsis and bloodstream infections (BSIs), increasing adoption of rapid molecular and syndromic diagnostics, greater focus on antimicrobial stewardship (AMS), and the expansion of biomarker-based testing. Healthcare providers are increasingly adopting automated blood culture systems, molecular diagnostic platforms, syndromic panels, immunoassays, and biomarker-based assays to support early diagnosis, pathogen identification, antimicrobial optimization, and improved patient outcomes. However, the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies continue to constrain broader adoption, particularly in cost-sensitive healthcare settings. At the same time, AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, and rapid point-of-care and decentralized testing are expected to create new growth opportunities. Clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel remain key challenges in the market.

The global sepsis diagnostics market is highly consolidated, with leading players including bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), Diasorin S.P.A (US), F. Hoffmann-La Roche AG (Switzerland), and Thermo Fisher Scientific, Inc. (US). These companies are strengthening their market positions through automated microbiology platforms, blood culture systems, molecular diagnostics, syndromic testing panels, biomarker assays, antimicrobial susceptibility testing, and expanded hospital laboratory solutions. Their competitive positioning is supported by strong installed bases, broad infectious disease testing portfolios, technological innovation, regulatory approvals, strategic partnerships, and geographic expansion.

To know about the assumptions considered for the study download the pdf brochure

BioMérieux SA

bioMérieux SA is a leading participant in the sepsis diagnostics market, supported by its strong infectious disease diagnostics portfolio, automated blood culture systems, microbial identification platforms, antimicrobial susceptibility testing solutions, and syndromic molecular diagnostics. The company maintains a strong position in hospital microbiology laboratories through platforms for bloodstream infection detection, pathogen identification, and antimicrobial stewardship. bioMérieux’s strength is further reinforced by its integrated approach across blood culture, molecular diagnostics, and sepsis-related laboratory workflows, enabling faster clinical decision-making and improved management of patients with suspected sepsis.

Becton, Dickinson and Company

Becton, Dickinson and Company is a major player in the sepsis diagnostics market, driven by its strong presence in blood culture, specimen collection, microbiology automation, and antimicrobial susceptibility testing. The company’s diagnostic solutions support the detection of bloodstream infections, improve laboratory workflow efficiency, and support antimicrobial stewardship programs. BD’s broad hospital customer base, global distribution network, and established microbiology platforms strengthen its position in the sepsis diagnostics market, particularly in centralized laboratories and high-volume hospital settings.

Danaher Corporation

Danaher Corporation is a key participant in the sepsis diagnostics market through its diagnostics businesses, which support infectious disease testing, molecular diagnostics, and clinical laboratory workflows. The company’s platforms are used across hospital and reference laboratories to enable rapid detection of infectious pathogens, supporting earlier diagnosis and treatment decisions in suspected sepsis cases. Danaher’s strong installed base, molecular testing capabilities, and presence across clinical diagnostics and laboratory automation strengthen its position in the global sepsis diagnostics market.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG is a leading player in the sepsis diagnostics market, supported by its broad capabilities in molecular diagnostics, immunoassays, and clinical chemistry testing. Roche’s diagnostics portfolio supports infectious disease testing, biomarker-based assessment, and laboratory decision-making for patients with suspected sepsis. The company’s strong global presence, automated testing platforms, and integrated diagnostics infrastructure position it well in hospital laboratories, where rapid, reliable testing is increasingly important for sepsis management and antimicrobial stewardship.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. is a key player in the sepsis diagnostics market, with capabilities spanning biomarker-based testing, molecular diagnostics, microbiology, and clinical laboratory solutions. The company supports sepsis diagnostics through technologies for infectious disease detection, inflammatory biomarker assessment, and laboratory testing workflows. Thermo Fisher’s strength is further reinforced by its broad diagnostics portfolio, global commercial reach, and leadership in biomarker-based testing, including applications that support early sepsis risk assessment, clinical decision-making, and antimicrobial stewardship.

Market Ranking

The sepsis diagnostics market is moderately consolidated, with leading companies accounting for a significant share of total market revenue in 2025. The top five companies collectively held a major share of the global sepsis diagnostics market, supported by a strong installed base in hospital microbiology laboratories and by automated blood culture systems, molecular diagnostics platforms, immunoassay capabilities, antimicrobial susceptibility testing solutions, and broad infectious disease testing portfolios. These companies continue to strengthen their positions through automated diagnostic platforms, rapid molecular and syndromic testing, biomarker-based sepsis assessment, antimicrobial stewardship-linked solutions, technological advancements, regulatory approvals, strategic partnerships, and geographic expansion initiatives.

Related Reports:

Sepsis Diagnostics Market by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]